Media & press kit.
Approved language, brand assets, executive bios, and a single media contact for fast turnaround.
Boilerplate
AblaView is a medical technology company developing the first polarization-sensitive optical coherence reflectometry (PS-OCR) platform for real-time guidance of cardiac ablation procedures. The system pairs a fiber-optic catheter with a console and a four-model Clinical AI Engine to deliver tissue characterization, contact assessment, lesion durability prediction, and safety detection during atrial fibrillation ablation. AblaView supports both radiofrequency and pulsed-field energy and is modality-agnostic at the guidance layer.
First-in-human results published in Europace (February 2025) demonstrated 100% specificity for durable PFA lesion prediction at three-month follow-up with no device-related serious adverse events. The AblaView platform was acquired outright by AblaView S.L. in 2026 with 70+ patents across 9 jurisdictions, 25 terabytes of proprietary clinical data, and the full technical team.
Investigational device. The AblaView® system is under preclinical/clinical investigation. It is not FDA approved nor CE labelled. Active FDA pre-submission programme for the Clinical AI Engine. Dated milestones are shared with qualified partners under NDA.
At a glance
Twelve years of underlying catheter R&D acquired outright from MedLumics S.L.
EU-headquartered, global clinical-advisor footprint.
Approved imagery and logos
- Primary logo on light backgrounds: download JPG
- Primary logo on dark backgrounds: download PNG
- Icon mark (favicon, 32×32 and up): download PNG
- Catheter product image: download JPG
Use of these assets is granted for editorial coverage of AblaView only. Please do not crop, recolour, or alter the logo. For brand exceptions or higher-resolution versions, write to info@ablaview.com.
Executive bios & headshots
Approved bios and high-resolution headshots are listed on the leadership page. For interviews, scheduling, or alternative-format requests, please contact us directly.
Media contact
Response within one business day for press enquiries.